Basis for the Management of Drug-resistant Helicobacter Pylori Infection

Overview

Journal Drugs

Specialty Pharmacology

Date 2004 Aug 27

PMID 15329036

Citations 22

Authors

Francis Megraud

Affiliations

Soon will be listed here.

Abstract

The discovery that most stomach diseases are a consequence of an Helicobacter pylori infection has completely changed the management of stomach diseases. Antibacterials are the treatment of choice in addition to proton pump inhibitors (PPIs) or ranitidine bismuth. We are now faced with the problem of antimicrobial resistance, which is the main cause of treatment failure. H. pylori acquires resistance essentially via point mutations, and today this phenomenon is found with most antibacterials. The most important resistance to consider is that to clarithromycin, since it is the first-choice antibacterial and clarithromycin resistance is highly clinically significant. Quadruple therapy or triple therapies with amoxicillin-metronidazole or tetracycline-metronidazole and a PPI or ranitidine bismuth can then be used despite a possible resistance to metronidazole if the strain is resistant to clarithromycin. Resistance to both clarithromycin and metronidazole may lead to the use of other combinations, i.e. amoxicillin-rifabutin, amoxicillin-levofloxacin or amoxicillin-furazolidone. Resistance to any of these drugs means their use must be avoided. In some instances, it may also be advisable to prescribe amoxicillin as the sole antibacterial, or to use a quadruple therapy with furazolidone instead of metronidazole. Although it is theoretically possible to cure a drug-resistant H. pylori infection, a practical limitation is the availability of the drugs in certain countries. Furthermore, the progressive increase in drug resistance warrants the need for new antibacterials in the near future.

Citing Articles

Green Chemistry Within the Circular Bioeconomy to Harness Chestnut Burr Extract's Synergistic Antimicrobial Activity Against .

Schiavone M, Barletta R, Trezza A, Geminiani M, Millucci L, Figura N Molecules. 2025; 30(2).

PMID: 39860194 PMC: 11767412. DOI: 10.3390/molecules30020324.

Rifabutin as salvage therapy for eradication: Cornerstones and novelties.

Borraccino A, Celiberto F, Pricci M, Girardi B, Iannone A, Rendina M World J Gastroenterol. 2022; 28(45):6356-6362.

PMID: 36533106 PMC: 9753051. DOI: 10.3748/wjg.v28.i45.6356.

Management of Helicobacter pylori infection in paediatric patients in Europe: results from the EuroPedHp Registry.

Le Thi T, Werkstetter K, Kotilea K, Bontems P, Cabral J, Cilleruelo Pascual M Infection. 2022; 51(4):921-934.

PMID: 36329342 PMC: 10352155. DOI: 10.1007/s15010-022-01948-y.

Experience with Rifabutin-Containing Therapy in 500 Patients from the European Registry on Management (Hp-EuReg).

Nyssen O, Vaira D, Saracino I, Fiorini G, Caldas M, Bujanda L J Clin Med. 2022; 11(6).

PMID: 35329984 PMC: 8949410. DOI: 10.3390/jcm11061658.

antibiotic sensitivity pattern in dyspeptic patients in Kano, Nigeria.

Bello A, Borodo M, Yakasai A, Tukur A S Afr J Infect Dis. 2021; 34(1):125.

PMID: 34485458 PMC: 8378098. DOI: 10.4102/sajid.v34i1.125.

References

Gerrits M, de Zoete M, Arents N, Kuipers E, Kusters J . 16S rRNA mutation-mediated tetracycline resistance in Helicobacter pylori. Antimicrob Agents Chemother. 2002; 46(9):2996-3000. PMC: 127406. DOI: 10.1128/AAC.46.9.2996-3000.2002. View

Maeda S, Yoshida H, Matsunaga H, Ogura K, Kawamata O, Shiratori Y . Detection of clarithromycin-resistant helicobacter pylori strains by a preferential homoduplex formation assay. J Clin Microbiol. 2000; 38(1):210-4. PMC: 88697. DOI: 10.1128/JCM.38.1.210-214.2000. View

Mendz G, Megraud F . Is the molecular basis of metronidazole resistance in microaerophilic organisms understood?. Trends Microbiol. 2002; 10(8):370-5. DOI: 10.1016/s0966-842x(02)02405-8. View

Isomoto H, Inoue K, Furusu H, Enjoji A, Fujimoto C, Yamakawa M . High-dose rabeprazole-amoxicillin versus rabeprazole-amoxicillin-metronidazole as second-line treatment after failure of the Japanese standard regimen for Helicobacter pylori infection. Aliment Pharmacol Ther. 2003; 18(1):101-7. DOI: 10.1046/j.1365-2036.2003.01659.x. View

Wong W, Gu Q, Lam S, Fung F, Lai K, Hu W . Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection. Aliment Pharmacol Ther. 2003; 17(4):553-60. DOI: 10.1046/j.1365-2036.2003.01459.x. View

Heep M, Beck D, Bayerdorffer E, Lehn N . Rifampin and rifabutin resistance mechanism in Helicobacter pylori. Antimicrob Agents Chemother. 1999; 43(6):1497-9. PMC: 89306. DOI: 10.1128/AAC.43.6.1497. View

Ebrahimi-Dariani N, Mirmomen S, Mansour-Ghanaei F, Noormohammadpoor P, Sotodehmanesh R, Haghpanah B . The efficacy of furazolidone-based quadruple therapy for eradication of Helicobacter pylori infection in Iranian patients resistant to metronidazole-based quadruple therapy. Med Sci Monit. 2003; 9(8):PI105-8. View

Treiber G, Wittig J, Ammon S, Walker S, van Doorn L, Klotz U . Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication: a randomized controlled trial (MACLOR study). Arch Intern Med. 2002; 162(2):153-60. DOI: 10.1001/archinte.162.2.153. View

Versalovic J, Shortridge D, Kibler K, Griffy M, Beyer J, Flamm R . Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori. Antimicrob Agents Chemother. 1996; 40(2):477-80. PMC: 163139. DOI: 10.1128/AAC.40.2.477. View

10.

Roghani H, Massarrat S, Shirekhoda M, Butorab Z . Effect of different doses of furazolidone with amoxicillin and omeprazole on eradication of Helicobacter pylori. J Gastroenterol Hepatol. 2003; 18(7):778-82. DOI: 10.1046/j.1440-1746.2003.03058.x. View

11.

Tomb J, White O, Kerlavage A, Clayton R, Sutton G, Fleischmann R . The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature. 1997; 388(6642):539-47. DOI: 10.1038/41483. View

12.

Debets-Ossenkopp Y, Sparrius M, Kusters J, Kolkman J, Vandenbroucke-Grauls C . Mechanism of clarithromycin resistance in clinical isolates of Helicobacter pylori. FEMS Microbiol Lett. 1996; 142(1):37-42. DOI: 10.1111/j.1574-6968.1996.tb08404.x. View

13.

Katelaris P, Forbes G, Talley N, Crotty B . A randomized comparison of quadruple and triple therapies for Helicobacter pylori eradication: The QUADRATE Study. Gastroenterology. 2002; 123(6):1763-9. DOI: 10.1053/gast.2002.37051. View

14.

Wong W, Wong B, Lu H, Gu Q, Yin Y, Wang W . One-week omeprazole, furazolidone and amoxicillin rescue therapy after failure of Helicobacter pylori eradication with standard triple therapies. Aliment Pharmacol Ther. 2002; 16(4):793-8. DOI: 10.1046/j.1365-2036.2002.01223.x. View

15.

Fakheri H, Malekzadeh R, Merat S, Khatibian M, Fazel A, Alizadeh B . Clarithromycin vs. furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a population with a high metronidazole resistance rate. Aliment Pharmacol Ther. 2001; 15(3):411-6. DOI: 10.1046/j.1365-2036.2001.00931.x. View

16.

Edwards D . Nitroimidazole drugs--action and resistance mechanisms. I. Mechanisms of action. J Antimicrob Chemother. 1993; 31(1):9-20. DOI: 10.1093/jac/31.1.9. View

17.

Grignon B, Tankovic J, Megraud F, Glupczynski Y, Husson M, Conroy M . Validation of diffusion methods for macrolide susceptibility testing of Helicobacter pylori. Microb Drug Resist. 2002; 8(1):61-6. DOI: 10.1089/10766290252913773. View

18.

Moore R, Beckthold B, Wong S, Kureishi A, Bryan L . Nucleotide sequence of the gyrA gene and characterization of ciprofloxacin-resistant mutants of Helicobacter pylori. Antimicrob Agents Chemother. 1995; 39(1):107-11. PMC: 162494. DOI: 10.1128/AAC.39.1.107. View

19.

Megraud F . H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut. 2004; 53(9):1374-84. PMC: 1774187. DOI: 10.1136/gut.2003.022111. View

20.

Marais A, Monteiro L, Occhialini A, Pina M, Lamouliatte H, Megraud F . Direct detection of Helicobacter pylori resistance to macrolides by a polymerase chain reaction/DNA enzyme immunoassay in gastric biopsy specimens. Gut. 1999; 44(4):463-7. PMC: 1727470. DOI: 10.1136/gut.44.4.463. View